Stelliam Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Stelliam Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,702,500	Closed	-$91.1M	–	48
2016 Q1	$91.1M	Buy	1,702,500 +437,500	+35%	+$25.7M	2.82%	15
2015 Q4	$83M	Sell	1,265,000 -380,000	-23%	-$23.5M	2.48%	16
2015 Q3	$92.9M	Buy	1,645,000 +285,000	+21%	+$18.5M	2.31%	14
2015 Q2	$80.4M	Buy	1,360,000 +270,000	+25%	+$16.7M	1.7%	21
2015 Q1	$67.9M	Sell	1,090,000 -165,000	-13%	-$9.59M	1.53%	28
2014 Q4	$72.2M	Buy	1,255,000 +337,500	+37%	+$18.8M	1.66%	21
2014 Q3	$49.3M	Buy	+917,500	New	+$48.6M	1.3%	40
2013 Q4	–	Sell	-1,837,500	Closed	-$69.4M	–	57
2013 Q3	$69.4M	Buy	1,837,500 +455,000	+33%	+$17.7M	3.31%	4
2013 Q2	$54.2M	Buy	+1,382,500	New	+$53.8M	2.94%	9

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Stelliam Investment Management's TEVA Position: Q2 2016 in Review

Stelliam Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 1,702,500 shares — an estimated $91.1M sold.

Stelliam Investment Management first reported a position in TEVA in Q2 2013 and held it in 9 quarters. The position peaked at $92.9M in Q3 2015. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Stelliam Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Stelliam Investment Management sold 1,702,500 Teva Pharmaceuticals shares in Q2 2016, an estimated $91.1M.
Stelliam Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Stelliam Investment Management's Teva Pharmaceuticals position peaked at $92.9M in Q3 2015.
813 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Stelliam Investment Management's 13F filing for Q2 2016, filed 15 Aug 2016.